Clinical trials: Urinary Tract Infections in Children
Schistosoma Haematobium
Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis
The purpose of this study is to evaluate the efficacy of praziquantel versus As+SMP (Co-Arinate FDC ®) in the treatment of Schistosoma haematobium in 6-15 year old Malian children.
- Trial name
- NCT00510159
- Testing
- Artesunate+Sulfamethoxypyrazine/pyrimethamin, Praziquantel
- Where
- Mali
- Volunteers
- 800 people
- Sponsor
- Dafra Pharma
Urinary Tract Infections in Children
A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.
This is a retrospectively-controlled clinical trial that will examine the rate of positive UTI cases among pediatrics entered into the Emergency Department and whose urine is withdrawn using the PedSCath Pediatric Sampling…
- Trial name
- NCT04763967
- Testing
- PedSCath Pediatric Urinary Catheter, Standard of Care
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Big Blue Biotech, Inc.
Complicated Urinary Tract Infections or Pyelonephritis
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with complicated urinary tract infections.
- Trial name
- NCT01110408
- Testing
- Doripenem, Cefepime, Amoxicillin/clavulanate potassium
- Where
- 38 sites in United States, Argentina and 10 more
- Volunteers
- 41 people
- Sponsor
- Janssen Research & Development, LLC
Complicated Urinary Tract Infections
Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)
This study will assess the safety, tolerability and efficacy of ceftazidime and avibactam (CAZ-AVI )versus cefepime in children from 3 months to less than 18 years old with complicated urinary tract infections.
- Trial name
- NCT02497781
- Testing
- Ceftazidime -avibactam, Cefepime
- Where
- 28 sites in United States, Czechia and 7 more
- Volunteers
- 97 people
- Sponsor
- Pfizer
Urinary Tract Infections in Children, Dexamethasone
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with…
- Conditions
- Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis
- Trial name
- NCT04654507
- Testing
- Dexamethasone Oral
- Where
- Qatar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Respiratory Tract Infections, Urinary Tract Infections in Children
PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)
To evaluate the safety and efficacy of treatment of children with acute bacterial infection disease with Ceftriaxone Sodium and Sulbactam Sodium for Injection in the condition of widely used, and provide the basis of adjusting…
- Trial name
- CRO-SBT (NCT04066621)
- Testing
- Ceftriaxone Sodium and Sulbactam Sodium for Injection
- Volunteers
- 30 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Acute Pyelonephritis, Complicated Urinary Tract Infection
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract…
- Trial name
- NCT06672978
- Testing
- Meropenem-Vaborbactam, Antibiotics
- Where
- 26 sites in United States, Bulgaria and 4 more
- Volunteers
- 66 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)